Under the GLP-1 class framing, it is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2, anyone pregnant or breastfeeding, and anyone with prior serious GLP-1 hypersensitivity
Funding LS is funded by a Rosetrees Trust and Pears Foundation Advancement Fellowship, SC is funded by a BBSRC LIDo-DTP PhD studentship (BB/T008709/1) and UD is funded by an MRC DTP PhD studentship (MR/W006774/1)
Potential Benefits of AOD-9604 Targeted Fat Reduction Directly stimulates the breakdown of stored fat in adipose tissue, particularly in stubborn areas resistant to diet and exercise Inhibited Fat Formation Prevents the creation of new fat cells, supporting long-term body composition improvements beyond initial fat loss No Blood Sugar Impact Does not affect glucose metabolism or insulin sensitivity, making it safe for patients concerned about metabolic disruption No IGF-1 Stimulation Avoids the cell proliferation effects associated with full HGH therapy while retaining the fat-specific benefits Improved Body Composition Helps shift the ratio of fat to lean tissue for a more defined, healthier physique Complementary to Diet and Exercise Enhances results from nutrition and training programs by targeting fat at the cellular level Potential Joint Support Emerging research suggests AOD-9604 may support cartilage health and repair Well-Tolerated Safety Profile Decades of research support AOD-9604's safety for fat reduction applications without significant adverse effects What Is AOD-9604 For
$28/visit maximum punch card value for dedicated recovery practitioners who prefer pay-as-you-go
Research models with chronic metabolic dysfunction often show NNMT overexpression that outpaces NAD+ synthesis capacity, creating a ceiling on how much metabolic improvement MOTS-c alone can produce
However, this difference was not found to be statistically significant (p = 0.100)
